International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies

EASI and IUIS/WHO/AF/CDC expert consensus producing 25 recommendations for ANA, anti-dsDNA, and specific autoantibody assessment. Emphasizes IIFA as reference method and importance of defining nuclear and cytoplasmic staining while acknowledging automated alternatives. Candidate notes: Formulated 25 recommendations covering ANA (1-13), anti-dsDNA (14-18), specific antibodies (19-23), and method validation (24-25). Emphasizes IIFA as a reference method and the importance of defining nuclear and cytoplasmic staining. Acknowledges need to incorporate alternative automated methods and to address discrepancies between methods. Goal is harmonization of local testing algorithms and improved bench-to-bedside communication. Suggests updated, more appropriate terminologies for autoantibodies to cellular antigens. Limits noted in the record: Full text paywalled in this run; findings taken from verified EuropePMC abstract (PMID 24126457). Authors list truncated for brevity vs full PubMed author string. A positive ANA is not a diagnosis. Claims in this record are not verified.

A positive ANA is not a diagnosis. Claims in this record are not verified.

source